CITY THERAPEUTICS, INC. Form 424B4 — Oct 16, 2026
City Therapeutics priced its IPO at $18.00 per share, selling 11,111,111 shares for gross proceeds of about $200 million ($181.5 million net) ahead of its Nasdaq Global Market debut under the symbol CTY. Underwriters Goldman Sachs, Jefferies, Stifel, and Oppenheimer hold a 30-day option on up to 1,666,666 additional shares. The clinical-stage RNAi biotech has no approved products and deepening losses: $58.5 million net loss in 2025 and $53.4 million in the first half of 2026, with an accumulated deficit of $142.5 million. It had roughly $141.9 million in cash as of September 30, 2026, which combined with IPO proceeds it expects to fund operations into late 2028.
Key figures
- Total Assets
- 208611000
- Cash Position
- 141900000
- Gross Proceeds
- 199999998
- Offering Price
- 18
- Shares Offered
- 11111111
- Shares Outstanding
- 51721168
- Cash Runway
- into late 2028 (with offering proceeds)
- Stock Split
- 1.0983-for-one effective October 8, 2026
- Net Loss2025
- $58.5 million
- Net Proceeds
- $181.5 million ($209.4 million with greenshoe)
- Net Loss H1 2026
- $53.4 million
- Greenshoe Shares
- 1666666
- Accumulated Deficit
- $142.5 million as of June 30, 2026
- Pre IPOEquity Raised
- $238.8 million
- Underwriting Discount Total
- 14000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.